VIDEO: Stelara can safely be used long-term to benefit patients with UC, Crohn’s

ByRemo Panaccione, MD

ByKate Burba

In a Healio video exclusive, Remo Panaccione, MD, discusses results from long-term, pooled analyses of adult patients treated with ustekinumab for inflammatory bowel disease.

“We know that Stelara (ustekinumab, Janssen) is a highly effective therapy in inflammatory bowel disease when it's either used first-line or in patients who have been exposed to other advanced therapies,” Panaccione, professor of medicine and director of the Inflammatory Bowel Disease Clinic at the University of Calgary, said. “This data really gives us the confidence that, in addition to its ability to be able to achieve efficacy across a multitude of endpoints, it can be used safely in the long-term to benefit our patients with inflammatory bowel disease.”

Reference:

Loftus E, et al. Presentation 888. Presented at: Digestive Disease Week; May 21-24, 2022; San Diego (hybrid meeting).

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews
Press Release

Disclosures: Panaccione reports financial relationships with Janssen.

Digestive Disease Week

Read more

VIDEO: Stelara can safely be used long-term to benefit patients with UC, Crohn’s

Related Content